Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2004

View Archived Issues

In vivo characterization of a rapid-acting thyroid hormone derivative

Chemokine microbicide formulation effective against HIV-1 in macaques

Influenza vaccine from Aventis now available for shipping

Dual neuroprotection from oxygen and nitrogen reactive species

PEP-005 shows high selectivity against leukemia

New phase I study of AT-1001 for Fabry's disease

Phase I studies begin for ABT-894 for neuropathic pain

OrthoLogic completes acquisition of Chrysalis BioTechnology

New indication approved for Hyzaar

European recommendation for extended dosing of Aranesp

GlycoGenesys enters agreements to close on funding from institutions

Yakult Honsha and Taiho to copromote oxaliplatin in Japan

Portola licenses Millennium's Factor Xa inhibitor program

Five series of chemokine CCR5 antagonists presented by GSK

AstraZeneca presents novel GSK-3 inhibitors for AD and other uses

Japanese researchers prepare and test a new antineoplastic antibiotic

New KDR and FGFR inhibitors with potential in solid tumor therapy

New epothilone derivatives in early development at Novartis

New glucagon antagonists discovered by Novo Nordisk scientists

Novel PAI-1 inhibitors produced by the microorganism Stachybotris atra

Human multidrug resistance protein 1 targeted in malignant cells

Frovatriptan provides relief for menstrual associated migraine

Merck & Co. and DOV enter agreement for triple uptake inhibitor development

NPS to promote Amgen's Kineret to rheumatologists

Approvable letter for ZyLET

Sinovac's phase I SARS study progresses

Dosing begins in phase I study of the thrombin inhibitor ARC-183

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.